GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tectonic Therapeutic Inc (NAS:TECX) » Definitions » Tax Provision

TECX (Tectonic Therapeutic) Tax Provision : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Tectonic Therapeutic Tax Provision?

Tectonic Therapeutic's tax provision for the three months ended in Dec. 2024 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.


Tectonic Therapeutic Tax Provision Historical Data

The historical data trend for Tectonic Therapeutic's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tectonic Therapeutic Tax Provision Chart

Tectonic Therapeutic Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Tax Provision
- - - -

Tectonic Therapeutic Quarterly Data
Dec21 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Tax Provision Get a 7-Day Free Trial - - - - -

Tectonic Therapeutic Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tectonic Therapeutic Business Description

Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 210, Watertown, MA, USA, 02472
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.